Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia.

Anne-Cécile GauchyMaxime HentzienAlain WynckelVictoire de MarcellusCyrielle RodierAlain DelmerAnne Quinquenel

Published in: Clinical case reports (2020)

Eculizumab may be considered as an emergency therapeutic option in refractory life-threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Keyphrases

iron deficiency
chronic kidney disease
multiple sclerosis
drug induced
emergency department
public health
acute myeloid leukemia
bone marrow
healthcare